Cargando…

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

INTRODUCTION: Chimeric antigen receptor T (CAR-T) cell therapy is an emerging treatment option for relapsed/refractory multiple myeloma (RRMM) that is a multi-step process involving various stakeholders. Appropriate education on the practical logistics is therefore paramount to ensure treatment succ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hungria, Vania, Piérola, Ana Alfonso, Filho, Jayr Schmidt, Crusoe, Edvan, Filho, Roberto José Pessoa de Magalhães, Maiolino, Angelo, Rodríguez-Otero, Paula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Hematologia e Hemoterapia 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244253/ https://www.ncbi.nlm.nih.gov/pubmed/36243623 http://dx.doi.org/10.1016/j.htct.2022.08.002

Ejemplares similares

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2021)

New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019)

Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel – ABHH monoclonal gammopathies committe
por: Hungria, Vania, et al.
Publicado: (2020)

Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012
por: Hungria, Vânia Tietsche de Moraes, et al.
Publicado: (2013)

COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM)
por: Garnica, Marcia, et al.
Publicado: (2021)

Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma()
por: Crusoé, Edvan de Queiroz, et al.
Publicado: (2021)

Multiple myeloma and central nervous system involvement: experience of a Brazilian center
por: Dias, Ana Luiza Miranda Silva, et al.
Publicado: (2018)

P954: MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY
por: Hungria, Vania, et al.
Publicado: (2023)

Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira – 2022. Part I
por: Maiolino, Angelo, et al.
Publicado: (2022)

For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
por: Silva, Luiza Soares Vieira da, et al.
Publicado: (2017)

Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life
por: Viol Ferreira Lopes, Maricy Almeida, et al.
Publicado: (2023)

Bilateral breast plasmacytoma: a clinical case report
por: Fischer, Thais Rodrigues da Cunha, et al.
Publicado: (2016)

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
por: Cury, Priscilla Cury de Camargo, et al.
Publicado: (2020)

CAR T-Cells in Multiple Myeloma Are Ready for Prime Time
por: Rodríguez-Otero, Paula, et al.
Publicado: (2020)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
por: Crusoe, Edvan De Queiroz, et al.
Publicado: (2020)

Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?
por: Crusoe, Edvan de Queiroz, et al.
Publicado: (2016)

Outcomes of autologous transplantation for multiple myeloma according to different induction regimens
por: de Queiroz Crusoe, Edvan, et al.
Publicado: (2014)

Oral health status of patients with multiple myeloma
por: Feitosa, Édila Figuerêdo, et al.
Publicado: (2020)

Can dentists detect multiple myeloma through oral manifestations?
por: Almeida, Thaís Miranda Xavier de, et al.
Publicado: (2018)

Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil
por: Salgado, Anna Beatriz dos Santos, et al.
Publicado: (2023)

PB1993: MULTIPLE MYELOMA BRAZILIAN REGISTER- HOW ABOUT THE TRANSPLANT ELIGIBLE PATIENTS?
por: Crusoe, E., et al.
Publicado: (2022)

Challenges for medical residency in hematology and transfusion medicine in Brazil
por: Maiolino, Angelo, et al.
Publicado: (2012)

The Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular seeks the implementation of, and access to, the CAR-T cell treatment in Brazil
por: Langhi Junior, Dante Mário, et al.
Publicado: (2021)

Lambda light chain-induced monoclonal gammopathy of renal significance, manifesting with Fanconi Syndrome and osteomalacia
por: Gutiérrez-Peredo, Gabriel Brayan, et al.
Publicado: (2022)

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
por: Rodriguez-Marquez, Paula, et al.
Publicado: (2022)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
por: Rodríguez-Lobato, Luis Gerardo, et al.
Publicado: (2020)

CAR-T cell therapy in myeloma: hopes and hurdles
por: Harousseau, Jean Luc
Publicado: (2023)

PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Weisel, Katja, et al.
Publicado: (2023)

Single-Institution Experience in Clinical Trials During the COVID-19 Pandemic in Spain: Not So Bad After All?
por: Rodriguez-Otero, Paula, et al.
Publicado: (2020)

Sustainable Sanitation Management Tool for Decision Making in Isolated Areas in Brazil
por: Magalhães Filho, Fernando J. C., et al.
Publicado: (2019)

Recent updates on CAR T clinical trials for multiple myeloma
por: Lin, Quande, et al.
Publicado: (2019)

Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma
por: Jasiński, Marcin, et al.
Publicado: (2021)

Copolymerized Natural Fibre from the Mesocarp of Orbignya phalerata (Babassu Fruit) as an Irrigating-Fertilizer for Growing Cactus Pears
por: Edvan, Ricardo, et al.
Publicado: (2020)

Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy
por: Brechbühl, Simon, et al.
Publicado: (2021)

Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma
por: Sjöstrand, Maria, et al.
Publicado: (2023)

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma
por: Alencar, Alvaro J., et al.
Publicado: (2021)

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy
por: Lee, Lydia, et al.
Publicado: (2023)

CAR T-cell therapy in multiple myeloma: more room for improvement
por: Teoh, Phaik Ju, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dn7j0fcvu1bi200me429jinalm